Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of polymerized hemoglobin in preparation of medicine for treating cerebral arterial thrombosis

A technology for ischemic stroke and hemoglobin, applied in the field of medicine, can solve the problems of insignificant overall curative effect, and achieve the effects of promoting the gradual recovery of nerve function, alleviating stenosis changes, and high oxygen carrying and releasing oxygen

Inactive Publication Date: 2022-01-28
REDPHARM BEIJING BIOPHARMACEUTICAL INST CO LTD +2
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently commonly used neuroprotective agents in clinical practice, edaravone, ganglioside, butylphthalide, vinpocetine, and citicoline, after network meta-analysis, it is believed that some of them can improve the function of neurological deficits in the short term, but overall The efficacy is not significant, further verification of the results is needed in high-quality head-to-head studies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polymerized hemoglobin in preparation of medicine for treating cerebral arterial thrombosis
  • Application of polymerized hemoglobin in preparation of medicine for treating cerebral arterial thrombosis
  • Application of polymerized hemoglobin in preparation of medicine for treating cerebral arterial thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] The present embodiment comprises the medicine of polymerized hemoglobin, and described medicine is that the following substances are dissolved in 1L of water for injection, and the specific proportions are as follows: polymerized hemoglobin 130.0g, sodium chloride 3.2g, potassium chloride 0.48g, calcium chloride dihydrate 0.15g, 0.23g sodium hydroxide, 1.75g ​​sodium lactate, 2.14g acetylcysteine.

Embodiment 2

[0045] This embodiment comprises the compound medicine of polymerized hemoglobin and neuroprotective agent, and described medicine is that the following substances are dissolved in 1L of water for injection, and the specific proportions are as follows: polymerized hemoglobin 65.0g, sodium chloride 6.6g, potassium chloride 0.3g, Calcium chloride dihydrate 0.2g, sodium hydroxide 0.48g, sodium lactate 3.0g, acetylcysteine ​​2.0g, edaravone 13.70mg.

Embodiment 3

[0047] The present embodiment comprises the medicine of polymerized hemoglobin, and described medicine is that the following substances are dissolved in 1L of water for injection, and the specific proportions are as follows: polymerized hemoglobin 65.0g, sodium chloride 6.6g, potassium chloride 0.3g, calcium chloride dihydrate 0.2g, 0.48g of sodium hydroxide, 3.0g of sodium lactate, 2.0g of acetylcysteine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of polymerized hemoglobin in preparation of a medicine for treating cerebral arterial thrombosis, the medicine is a hemoglobin oxygen carrier and is also a colloidal solution, and the particle size of the polymerized hemoglobin is only one thousandth of that of red blood cells. Small-dose perfusion does not bring tissue damage and cell death caused by reperfusion to the brain, but can relieve blood shortage caused by artery occlusion; meanwhile, hemoglobin carries out oxygen loading-oxygen unloading from the lung to tissues and organs, and targeted blocking is carried out on the pathophysiological process caused by ischemia and hypoxia of the brain; therefore, the nerve cells of the ischemic penumbra are saved, the death number of the nerve cells is reduced, and the nerve protection effect is achieved. A neuroprotective agent can also be added into the medicine disclosed by the invention to prepare a compound medicine, the protection effect on ischemic penumbra nerve cells is more obvious, and the 'therapeutic window' of stroke after rt-PA intravenous thrombolysis for 6 hours can be prolonged.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of polymerized hemoglobin in the preparation of medicine for treating ischemic stroke. Background technique [0002] The oxygen consumption of normal adult brain tissue accounts for 20% to 30% of the whole body's oxygen consumption. The energy source of brain tissue is mainly the aerobic metabolism of sugar, and there is almost no energy reserve, so it is very sensitive to ischemia and hypoxia damage. Acute ischemic stroke (AIS) refers to a clinical category of ischemia and hypoxic necrosis in local brain tissue caused by various causes of cerebral blood supply disorders, followed by corresponding neurological deficits. syndrome. It has the characteristics of "three highs" of high morbidity, high disability and high mortality. Research by Devin et al showed that more than 70% of AIS is permanent ischemic stroke (pMCAO). [0003] AIS is the most c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/42A61K45/06A61K9/10A61K47/02A61K47/12A61K47/18A61P9/10A61P25/00A61K31/4152A61K31/7032A61K31/365A61K31/4375A61K31/7068
CPCA61K38/42A61K45/06A61K31/4152A61K31/7032A61K31/365A61K31/4375A61K31/7068A61K9/10A61K47/02A61K47/12A61K47/183A61P9/10A61P25/00A61K2300/00
Inventor 游可为李剑波张彦鹏石松王文刚
Owner REDPHARM BEIJING BIOPHARMACEUTICAL INST CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com